Indoor mold and mycotoxin exposure is one of the most contested areas in clinical medicine — with a significant gap between the wellness/functional medicine community's attribution of broad symptom complexes to mold exposure and mainstream medicine's more skeptical position based on available epidemiological evidence. Understanding what the clinical literature actually demonstrates — which effects are well-supported, which are plausible but uncertain, and which are contested — is essential for clinical counseling.
Well-Established Health Effects
The effects of indoor mold exposure with strong clinical evidence are respiratory: multiple meta-analyses confirm that visible mold and dampness in homes significantly increases risk of asthma exacerbation (OR 1.4–2.2), allergic rhinitis, and respiratory infections — primarily via inflammatory and allergenic (IgE-mediated) mechanisms rather than direct mycotoxin toxicity. The WHO guidelines on indoor dampness and mold (2009) conclude that the association with respiratory disease is causal. Allergic bronchopulmonary aspergillosis (ABPA): a genuine systemic fungal hypersensitivity in asthmatic and CF patients — a well-defined clinical entity requiring antifungal treatment. Hypersensitivity pneumonitis (HP): immune-mediated lung inflammation from repeated organic dust inhalation — occupational mold exposures can cause HP.
The CIRS Controversy and What the Evidence Shows
Chronic Inflammatory Response Syndrome (CIRS) — a diagnosis promoted primarily by Ritchie Shoemaker MD — attributes a broad symptom complex (fatigue, cognitive impairment, musculoskeletal pain, visual changes) to mycotoxin-triggered chronic inflammation in genetically susceptible individuals. The proposed diagnostic framework includes HLA genotyping, TGF-β1, MMP-9, VIP, and other biomarkers. Evidence assessment: a 2019 AAAAI position statement and a 2021 American Industrial Hygiene Association review concluded that the CIRS diagnostic framework lacks validation in peer-reviewed studies and should not guide clinical management. This does not mean mold exposure cannot cause symptoms — the respiratory evidence is clear — but the systemic CIRS model is not supported by current evidence. Urine mycotoxin testing (ELISA-based home testing marketed by functional medicine providers): not validated against clinical outcomes, with high false-positive rates; the American Industrial Hygiene Association advises against clinical decision-making based on these tests. For clinical environmental health assessments, our PPE catalog includes appropriate respiratory protection for healthcare workers in water-damaged environments.
